GleamWall
中文EN

XCUR EXICURE, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1698530 · Fiscal year ends 12/31

Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-97.7%
TTM net income YoY-235.0%
TTM EPS YoY65.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,228.2%
Net margin-801.4%
FCF margin—
EBITDA margin-1,222.6%

Returns

ROE-132.6%
ROA-34.0%
ROIC (approx.)-326.7%
Asset turnover0.04x

Leverage & solvency

Liabilities / assets85.5%
Debt / equity0.00x
Current ratio0.71x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$174,000$312,000$655,000$888,000$935,000$808,000$0$0
SG&A expense$889,000$1.29M$1.60M$1.50M$1.51M$2.22M$1.44M$1.43M
Operating income-$1.05M-$1.64M-$2.26M-$2.39M-$2.51M$2.92M-$7.59M-$2.57M
Interest expense——$1,000$0——$0$12,000
Pretax income-$1.12M-$1.83M-$3.53M-$2.44M-$2.62M$3.01M-$7.18M-$1.08M
Income tax$0$0-$634,000$0$0$0$0$8,000
Net income-$1.12M-$1.83M-$2.90M-$2.44M-$2.62M$3.01M-$7.18M-$1.09M
EBITDA-$1.01M-$1.59M-$2.23M-$2.31M-$2.44M$2.98M-$7.58M-$2.56M
EPS (basic)-0.18-0.29—-0.39-0.410.49—-0.57
EPS (diluted)-0.18-0.29—-0.39-0.410.49—-0.57
Weighted avg. shares (diluted)6.37M6.37M—6.32M6.32M6.18M—1.90M
Balance sheet
Cash & equivalents$1.72M$2.60M$3.75M$4.44M$7.86M$10.42M$12.51M$951,000
Current assets$2.32M$3.53M$4.62M$5.44M$8.65M$11.30M$13.67M$2.60M
PP&E, net$178,000$219,000$306,000$527,000$712,000$565,000$26,000$33,000
Goodwill$4.40M$4.40M$4.40M$3.34M$3.34M$3.34M$0—
Intangibles$3.78M$3.78M$3.78M$3.78M$3.78M$3.78M$0—
Total assets$11.40M$12.76M$14.04M$15.27M$18.74M$20.68M$15.06M$10.63M
Current liabilities$4.17M$4.46M$3.89M$2.77M$4.57M$3.89M$3.07M$3.65M
Total liabilities$10.42M$10.66M$10.12M$8.34M$9.88M$9.30M$8.28M$9.09M
Shareholders' equity$977,000$2.10M$3.93M$6.93M$8.86M$11.38M$6.77M$1.54M
Shares outstanding6.37M6.37M6.37M6.37M6.32M6.32M6.03M2.17M
Cash flow statement
Operating cash flow-$887,000-$1.14M-$1.15M-$3.53M-$2.28M-$1.60M-$845,000-$449,000
Capital expenditure——-$213,000-$106,000——$0$0
Free cash flow——-$934,000-$3.42M——-$845,000-$449,000
Investing cash flow$0$0$455,000$108,000-$280,000-$2.09M$0$0
Financing cash flow$0$0$0$0$0$1.60M$12.40M$0
Depreciation & amortization$40,000$49,000$28,000$82,000$71,000$61,000$7,000$7,000
Stock-based compensation——$1,000$0$1,000$0$6,000$5,000

Free plan shows the latest 8 periods; Pro shows all 42 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.